• Japanese
  • Korean
  • Chinese
Cover Image

Dermatology Partnering Terms and Agreements

The Dermatology Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter dermatology partnering deals. The majority of deals are discovery, preclinical or development stage whereby the licensee obtains a right or an option right to license the licensors dermatology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest dermatology deals and contracts announced in the healthcare sectors.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The report includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. The initial chapters of this report provide an orientation of dermatology dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in dermatology dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading dermatology deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of dermatology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all dermatology deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all dermatology partnering deals signed and announced since 2009. The chapter is organized by specific dermatology therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all dermatology partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in dermatology partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of dermatology technologies and products.

Key benefits

Dermatology Partnering Terms and Agreementsprovides the reader with the following key benefits:

  • In-depth understanding of dermatology deal trends since 2009
  • Access dermatology deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between dermatology partner companies
  • Comprehensive access to over 1500 links to actual dermatology deals entered into by the world's biopharma companies
  • Indepth review of dermatology deals entered into by the leading fifty bigpharma companies
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner dermatology opportunities
  • Uncover companies actively partnering dermatology opportunities

Report scope

Dermatology Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to dermatology trends and structure of deals entered into by leading companies worldwide.

Dermatology Partnering Terms and Agreements includes:

  • Trends in dermatology dealmaking in the biopharma industry since 2009
  • Analysis of dermatology deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of dermatology deal contract documents
  • Comprehensive access to over 1500 dermatology deal records
  • The leading dermatology deals by value since 2009
  • Most active dermatology dealmakers since 2009

In Dermatology Partnering Terms and Agreements, available deals and contracts are listed by:

  • Headline value o Upfront payment value
  • Royalty rate value o Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in dermatology dealmaking

  • 2.1. Introduction
  • 2.2. Dermatology partnering over the years
  • 2.3. Bigpharma dermatology dealmaking activity
  • 2.4. Bigpharma not active in dermatology
  • 2.5. Dermatology partnering by deal type
  • 2.6. Dermatology partnering by industry sector
  • 2.7. Dermatology partnering by stage of development
  • 2.8. Dermatology partnering by technology type
  • 2.9. Dermatology partnering by dermatology indication
  • 2.10. Average deal terms for dermatology
    • 2.10.1 Dermatology headline values
    • 2.10.2 Dermatology upfront payments
    • 2.10.3 Dermatology milestone payments
    • 2.10.4 Dermatology royalty rates

Chapter 3 - Leading dermatology deals

  • 3.1. Introduction
  • 3.2. Top dermatology deals by value
  • 3.3. Top dermatology deals involving bigpharma

Chapter 4 - Bigpharma dermatology deals

  • 4.1. Introduction
  • 4.2. How to use bigpharma partnering deals
  • 4.3. Bigpharma dermatology partnering company profiles
    • Abbott
    • Actavis
    • Actelion
    • Allergan
    • Amgen
    • Astellas
    • AstraZeneca
    • Baxter International
    • Bayer
    • Bristol-Myers
    • Squibb C
    • elgene
    • Eli Lilly
    • Endo Pharmaceuticals
    • Forest Laboratories
    • Galderma
    • GlaxoSmithKline
    • Hospira
    • Johnson & Johnson
    • Merck & Co
    • Merck KGaA
    • Mitsubishi Tanabe
    • Novartis
    • Pfizer
    • Roche
    • Sanofi
    • Shionogi
    • Shire
    • Teva
    • Warner Chilcott
    • Watson

Chapter 5 - Dermatology partnering contracts directory

  • 5.1. Introduction
  • 5.2. By deal type
    • Asset purchase
    • Assignment
    • Bigpharma outlicensing
    • Co-development
    • Collaborative R&D
    • Co-market
    • Contract service
    • Co-promotion
    • Development
    • Distribution
    • Equity purchase
    • Joint venture
    • Licensing
    • Litigation
    • Loan
    • Manufacturing
    • Marketing
    • Option
    • Promotion
    • Research
    • Settlement
    • Sub-license
    • Supply
    • Termination
  • 5.3. By stage of development
    • Discovery
    • Formulation
    • Marketed
    • Phase I
    • Phase II
    • Phase III
    • Preclinical
  • 5.4. By technology type
    • Antibodies
    • Assays
    • Biologicalcompounds
    • Biomaterials
    • Clinical testing
    • Devices
    • Diagnostics
    • DNA probes
    • Drug delivery
    • Enabling technology
    • Equipment
    • Genomics
    • Natural product
    • Oligonucleotide
    • Orphan drug
    • Peptides
    • Processes
    • Recombinant DNA
    • Regenerative medicine
    • Research services
    • Research supplies
    • Screening
    • Small molecules
    • Stem cells

Chapter 6 - Dermatology dealmaking by indication

  • 6.1. Introduction
  • 6.2. Deals by therapeutic indication
    • Dermatology
    • Acne
    • Actinickeratosis
    • Angioedema
    • Burns
    • Cellulitis
    • Cosmetics
    • Dermatitis
    • Diabetic foot ulcer
    • Eczema Hair disorders
    • Impetigo
    • Itching
    • Nail disorders
    • Psoriasis Rosacea
    • Sun damage
    • Rash Scar
    • Venous ulcer
    • Wound healing
    • Wrinkles

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Directory of dermatology deals by company A-Z 2007-2012
  • Appendix 2 - Directory of dermatology deals by deal type 2007-2012
    • Asset purchase
    • Assignment
    • Bigpharma outlicensing
    • Co-development
    • Collaborative R&D
    • Co-market
    • Contract service
    • Co-promotion
    • CRADA
    • Cross-licensing
    • Development
    • Distribution
    • Equity purchase
    • Evaluation
    • Grant
    • Joint venture
    • Licensing
    • Litigation
    • Loan
    • Manufacturing
    • Manufacturing - OEM
    • Marketing
    • Material transfer
    • Option
    • Promotion
    • Research
    • Royalty financing
    • Settlement
    • Spin out
    • Sub-license
    • Supply
    • Technology transfer
    • Termination
    • Warranty
  • Appendix 3 - Directory of dermatology deals by stage of development 2007-2012
  • Appendix 4 - Directory of dermatology deals by technology type 2007
  • Appendix 5 - Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent titles from CurrentPartnering
  • Order Form - Reports

Table of figures

  • Figure 1: Dermatology partnering since 2009
  • Figure 2: Bigpharma - top 50 - dermatology deals 2007 to 2012
  • Figure 3: Bigpharma dermatology deal frequency - 2007 to 2012
  • Figure 4: Inactive bigpharma in dermatology 2007-2012
  • Figure 5: Dermatology partnering by deal type since 2009
  • Figure 6: Dermatology partnering by industry sector since 2009
  • Figure 7: Dermatology partnering by stage of development since 2009
  • Figure 8: Dermatology partnering by technology type since 2009
  • Figure 9: Dermatology partnering by dermatology target since 2009
  • Figure 10: Dermatology deals with a headline value
  • Figure 11: Dermatology deal headline value distribution, US$million - discovery stage
  • Figure 12: Dermatology deal headline value distribution, US$million - preclinical stage
  • Figure 13: Dermatology deal headline value distribution, US$million - phase I stage
  • Figure 14: Dermatology deal headline value distribution, US$million - phase II stage
  • Figure 15: Dermatology deal headline value distribution, US$million - phase III stage
  • Figure 16: Dermatology deal headline value distribution, US$million - regulatory stage
  • Figure 17: Dermatology deal headline value distribution, US$million - marketed stage
  • Figure 18: Summary median headline value by stage of development, 2007-2012
  • Figure 19 Dermatology deals with upfront payment values
  • Figure 20: Dermatology deal upfront payment distribution, US$million - discovery stage
  • Figure 21: Dermatology deal upfront payment distribution, US$million - preclinical stage
  • Figure 22: Dermatology deal upfront payment distribution, US$million - phase I stage
  • Figure 23: Dermatology deal upfront payment distribution, US$million - phase II stage
  • Figure 24: Dermatology deal upfront payment distribution, US$million - phase III stage
  • Figure 25: Dermatology deal upfront payment distribution, US$million - regulatory stage
  • Figure 26: Dermatology deal upfront payment distribution, US$million - marketed stage
  • Figure 27: Summary median upfront payments by stage of development, 2007-2012
  • Figure 28: Dermatology deals with milestone payments
  • Figure 29: Dermatology deal milestone distribution, US$million - discovery stage
  • Figure 30: Dermatology deal milestone distribution, US$million - preclinical stage
  • Figure 31: Dermatology deal milestone distribution, US$million - phase I stage
  • Figure 32: Dermatology deal milestone distribution, US$million - phase II stage
  • Figure 33: Dermatology deal milestone distribution, US$million - phase III stage
  • Figure 34: Dermatology deal milestone distribution, US$million - regulatory stage
  • Figure 35: Dermatology deal milestone distribution, US$million - marketed stage 94
  • Figure 36: Dermatology deals with royalty rates, %
  • Figure 37: Dermatology deal royalty rate distribution, US$million - discovery stage
  • Figure 38: Dermatology deal royalty rate distribution, US$million - preclinical stage
  • Figure 39: Dermatology deal royalty rate distribution, US$million - phase I stage
  • Figure 40: Dermatology deal royalty rate distribution, US$million - phase II stage
  • Figure 41: Dermatology deal royalty rate distribution, US$million - phase III stage
  • Figure 42: Dermatology deal royalty rate distribution, US$million - regulatory stage
  • Figure 43: Summary median royalty rate by stage of development, 2007-2012
  • Figure 44: Top dermatology deals by value since 2009
  • Figure 45: Top dermatology deals signed by bigpharma value since 2009
  • Figure 46: Online partnering resources
  • Figure 47: Forthcoming partnering events
Show More
Pricing
Get Notified
Email me when related reports are published